New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2013
09:02 EDTKBIOKaloBios announces preliminary phase 1 results of KB004 study
KaloBios Pharmaceuticals announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody, which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study. The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity.
News For KBIO From The Last 14 Days
Check below for free stories on KBIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
07:35 EDTKBIONeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use